CDH1 and cancer: Tsuiji et al. used benzyl-α-GalNAc, an O-glycosylation modulator, to inhibit the extension of O-glycans on the cancer-associated glycoprotein dysadherin, thereby inhibiting the stable expression of dysadherin, which in turn leads to upregulation of E-cadherin expression and increased cell‒cell adhesion [51].